<DOC>
	<DOCNO>NCT01100723</DOCNO>
	<brief_summary>This trial design determine use computer algorithm design optimize mineral outcome dialysis patient increase number patient achieve desired target endpoint calcium , phosphorus parathyroid hormone .</brief_summary>
	<brief_title>Trial Optimize Mineral Outcomes Dialysis Patients</brief_title>
	<detailed_description>It hypothesis computerized dose protocol incorporate cinacalcet vitamin D analogue achieve significantly good control mineral bone parameter currently observe dialysis facility . This trial test hypothesis . Objectives Primary Objectives 1 . Compare percent patient achieve intact parathyroid hormone ( PTH ) target ≤ 300 pg/ml application computerize dose protocol management chronic kidney diseases mineral bone disorder ( CKD-MBD ) . 2 . Compare percent patient achieve phosphorus ≤ 5.5 mg/dL application computerize dose protocol management CKD-MBD . Secondary Objectives 1 . Compare percent patient achieve intact PTH target ≤ 450 pg/ml application computerize dose protocol management CKD-MBD . 2 . Compare percent patient achieve phosphorus ≤ 4.5 mg/dL application computerize dose protocol management CKD-MBD . 3 . Compare percent patient achieve calcium ≤ 10.1 mg/dL application computerize dose protocol management CKD-MBD . 4 . Compare percent patient cinacalcet vitamin D analogue baseline 6 12 month application computerize dose protocol management CKD-MBD . 5 . Compare mean standard deviation ( SD ) baseline 6 12 month PTH , calcium phosphorus . 6 . Compare total monthly average weekly ( patient medication ) active vitamin D analogue dose baseline 6 12 month ( convert mcg per month paricalcitol ) application computerize dose protocol management CKD-MBD . 1 mcg paricalcitol = 0.5 mcg doxercalciferol 7 . Compare number patient calcium non-calcium binder baseline 6 12 month application computerize dose protocol management CKD-MBD . 8 . Determine percent patient non-compliant oral cinacalcet percent unable tolerate dose require algorithm achieve target outcome</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Men woman 18 year age old On outpatient hemodialysis Have level understanding willingness cooperate study personnel Able provide inform consent Currently enrol another interventional clinical trial Are pregnant , plan become pregnant study period , breastfeed Planned parathyroidectomy within 6 month Planned kidney transplant within 6 month Life expectancy &lt; 6 month Patient decline participation Liver function test &gt; 2 time upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>secondary hyperparathyroidism</keyword>
	<keyword>calcium</keyword>
	<keyword>phosphorus</keyword>
	<keyword>ESRD</keyword>
	<keyword>CKD</keyword>
	<keyword>mineral disorder</keyword>
</DOC>